Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Doxorubicin,DOX2020-US-01,2020,USA,MDV,350,62,55.0,45.0,27.5,32.0,85.0,12.0,20.0,35.0,30.0,15.0,60.0,25.0,10.0,5.0,25.0,40.0,30.0,18.0,7.0,3.0,9.0,4.0,45.0,55.0,60.0,FAC,AC,AC-T,TC,20.0,15.0,10.0,40.0,70.0,50.0,15.0,45.0,40.0,65.0,2
Doxorubicin,DOX2021-EU-02,2021,Germany,Claim Database,420,68,60.0,40.0,26.8,28.0,78.0,15.0,18.0,32.0,35.0,15.0,55.0,30.0,10.0,5.0,22.0,38.0,32.0,20.0,8.0,4.0,10.0,5.0,40.0,60.0,55.0,EC,FEC,Docetaxel/Cyclophosphamide,CMF,22.0,18.0,12.0,45.0,75.0,55.0,10.0,50.0,40.0,70.0,1
Doxorubicin,DOX2022-ASIA-03,2022,Japan,MDV,280,70,58.0,42.0,24.5,25.0,80.0,10.0,22.0,38.0,25.0,15.0,65.0,20.0,10.0,5.0,28.0,42.0,25.0,15.0,6.0,2.0,8.0,3.0,50.0,50.0,70.0,FEC,EC,Docetaxel/Cyclophosphamide,CMF,25.0,20.0,15.0,35.0,65.0,45.0,20.0,40.0,40.0,75.0,3
Doxorubicin,DOX2023-CA-04,2023,Canada,Claim Database,300,65,52.0,48.0,28.0,30.0,82.0,13.0,19.0,33.0,33.0,15.0,58.0,27.0,10.0,5.0,24.0,39.0,29.0,17.0,7.5,3.5,9.5,4.5,42.0,58.0,62.0,AC,Taxol/AC,AC-T,TC,21.0,16.0,11.0,41.0,71.0,51.0,14.0,46.0,40.0,67.0,2.5
